Physician profile
Kaitlin E Stover
NPI 1720618291
$6,534.92
in general payments reported to CMS, 2019-2025
27 companies · $1,482 in 2025
The $1,482 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,106 · 2022: $1,505 · 2023: $1,368 · 2024: $1,073 · 2025: $1,482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,923.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,236.22 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $918.37 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $794.61 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $553.63 | 2021-2025 | Caplyta |
| Alkermes, INC. | $315.85 | 2021-2023 | Aristada, Lybalvi |
| Lundbeck LLC | $313.81 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $303.73 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $295.65 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $268.16 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Corium, LLC | $236.82 | 2021-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $216.88 | 2025 | Fanapt |
| Tris Pharma INC | $144.17 | 2024-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $142.70 | 2021-2024 | Jornay Pm |
| Neos Therapeutics, LP | $132.67 | 2021-2024 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Almatica Pharma LLC | $132.55 | 2023-2025 | Loreev Xr |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $90.00 | 2021-2024 | Spravato |
| Axsome Therapeutics, INC. | $82.73 | 2022-2025 | Auvelity |
| Janssen Biotech, INC. | $51.82 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $51.19 | 2024-2025 | Cobenfy |
| Luye Pharma (USA) LTD. | $50.58 | 2025 | Erzofri Extended-Release |
| Owp Pharmaceuticals, INC. | $41.75 | 2021 | |
| Idorsia Pharmaceuticals US INC | $40.70 | 2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $40.62 | 2021 | |
| Avanir Pharmaceuticals, INC. | $31.18 | 2022 | |
| Intercept Pharmaceuticals, INC. | $19.73 | 2021 | |
| Collegium Pharmaceutical, INC. | $14.98 | 2025 | Jornay Pm |
| Eisai INC. | $13.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlin Stover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.